Forte Biosciences (FBRX) Other Non-Current Liabilities (2016 - 2026)
Forte Biosciences' (FBRX) quarterly Other Non-Current Liabilities came in at $1.5 million in Q1 2026, up 42.33% on a QoQ basis from $1.0 million in Q4 2025.
Forte Biosciences (FBRX) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has 5 years of Other Non-Current Liabilities data on file, last reported at $1.5 million in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $1.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $1.5 million, up from $1.0 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for FBRX reached as high as $1.5 million in Q1 2026 and fell as low as $1.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.04 Mn |
| Dec 31, 2019 | 81,000.00 |
| Sep 30, 2019 | 81,000.00 |
| Mar 31, 2017 | 67,000.00 |
| Dec 31, 2016 | 126,000.00 |